Zobrazeno 1 - 10
of 5 579
pro vyhledávání: ''
Autor:
Yue Xing, Hong Xiang Zuo, Ming Yue Li, Zhi Hong Zhang, Juan Ma, Xuejun Jin, Jing Ying Wang, Hong Lan Jin
Publikováno v:
British Journal of Pharmacology. 179:1887-1907
ZFP91 positively regulates IL-1β production in macrophages and may be a potential therapeutic target to treat inflammatory-related diseases. We investigated whether this process is modulated by convallatoxin, which is a cardiac glycoside isolated fr
Autor:
Patrick Trouillas, J. Javellaud, Václav Bazgier, Nicolas Picard, Pierre Marquet, Petra Čechová, Souleiman El Balkhi, Michal Otyepka, Franck Saint-Marcoux, Roland Lawson, Eliès Zarrouk
Publikováno v:
British Journal of Pharmacology. 180:829-842
BACKGROUND AND PURPOSE Opioids and benzodiazepines are frequently combined in medical as well as in non-medical contexts. At high doses, such combinations often result in serious health complications attributed to pharmacodynamics interactions. Here,
Publikováno v:
British Journal of Pharmacology. 179:1338-1352
BACKGROUND AND PURPOSE Prostacyclin mimetics express potent vsoactive effects via prostanoid receptors which are not defined unequivocally, as to date no study has considered sex as a factor. The aim of this study was to determine the contribution of
Autor:
Xin Rui Lim, Eamonn Bradley, Gerard P. Sergeant, Keith D. Thornbury, Caoimhin S. Griffin, Mark A. Hollywood
Publikováno v:
British Journal of Pharmacology. 179:1082-1101
Background and purpose Corpus cavernosum smooth muscle (CCSM) exhibits phasic contractions that are coordinated by ion channels. Mouse models are commonly used to study erectile dysfunction, but there are few published electrophysiological studies of
Autor:
Jin-Zi Ji, Peng-Xin Ge, Qiong-Yu Mi, Ting Zhu, Ting Tai, Hong-Guang Xie, Li-Ping Jiang, Yi-Fei Li
Publikováno v:
British Journal of Pharmacology. 179:46-64
Background and purpose Overweight or obese patients exhibit poorer platelet responses to clopidogrel; however, the mechanisms behind this phenotype remain to be elucidated. Here, we sought to dissect whether and why obesity could affect the metabolic
Publikováno v:
British Journal of Pharmacology. 178:4501-4517
BACKGROUND AND PURPOSE The ability of the muscarinic cholinergic antagonist atropine to inhibit myopia development in humans and animal models would suggest that cholinergic hyperactivity may underlie myopic growth. To test this, we investigated whet
Autor:
Nicholas S. Kirkby, Ivana Vojnovic, Chih-Chin Shih, Paul C Armstrong, Timothy D. Warner, Jane A. Mitchell, Melissa V. Chan
Publikováno v:
British Journal of Pharmacology. 178:4758-4771
Background and purpose P2Y12 receptor antagonists reduce platelet aggregation and the incidence of arterial thrombosis. Adenosine signalling in platelets directly affects cyclic nucleotide tone, which we have shown to have a synergistic relationship
Autor:
Nikolina Kutinová Canová, J Pozniak, Ondřej Slanař, Martin Šíma, Tereza Boleslavská, Tomas Grus, Jan Bosák, Jana Královičová, Tomáš Křížek, Petr Kozlík, František Štěpánek, Pavel Ryšánek, Peter Lukáč, Jaroslava Roušarová
Publikováno v:
British Journal of Pharmacology. 178:4663-4674
Background and purpose Lymphatic transport of drugs after oral administration is an important mechanism for absorption of highly lipophilic compounds. Direct measurement in lymph duct cannulated animals is the gold standard method, but non-invasive c
Autor:
Xiaofang Gao, Zuofeng Liu, Yu Wang, Minhui Li, Ping Li, Pengfan Qie, Dong Renhan, Xu Gaojie, Lijuan Su, Peng Jian, Bin Guang, Sisi Yu, Siyuan Liu, Huang Sheng, Jin Liu, Siqi Yu, Hu Wen, Tai Yang
Publikováno v:
British Journal of Pharmacology. 178:4741-4757
BACKGROUND AND PURPOSE Aberrant lipid metabolism is recognized as a key feature of cancer cells. Our initial research on MS-based analysis of lipids in a multiple myeloma (MM) cell line showed a significant accumulation of lipids in multiple myeloma
Publikováno v:
British Journal of Pharmacology. 178:4389-4407
Background and purpose The multikinase inhibitor sorafenib is a first-line drug for advanced hepatocellular carcinoma. The response to sorafenib varies among hepatocellular carcinoma patients and many of the responders suffer from reduced sensitivity